

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

requirements from Antigenics through 2014. Antigenics will also transfer manufacturing technologies to GSK under the supply agreement. GSK will make payments contingent upon successful milestone achievements, and will pay royalties to Antigenics on net sales for a period of at least 10 years after first commercial sale under the supply agreement.

Item 7.01 Regulation FD Disclosure

On July 10, 2006, Antigenics Inc. issued a press release announcing the execution of the agreements described in Item 1.01 above. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated July 10, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: July 10, 2006

By: /s/ Garo H. Armen, Ph.D.

Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer

EXHIBIT INDEX

| Exhibit No. ----- | Description of Exhibit ----- |
|----------------------|-----------------------------------|
| 99.1 | Press Release dated July 10, 2006 |